Research funding

Czech Science Foundation

• 16-26849S - Interactions of protein kinase inhibitors with drug transporters and biotransformation enzymes; role in overcoming resistance in anticancer therapy (2016-2018)
• 20-20414Y - Study on the role of novel targeted breast and lung anticancer drugs in the phenomenon of pharmacokinetic drug resistance (2020 – 2022)

Grant Agency of Charles University

• 114909/C – Study of interactions of CDK inhibitors with ABCG2 (BCRP) drug transporter (2009 – 2011)
• 137010/C – Localization and function of organic cation transporter 3 (OCT3) in the rat placenta (2010 – 2012)
• 700912/C – Study of interactions of cyclin-dependent kinase inhibitors with ABCB1 drug efflux transporter (2012 – 2014)
• 1568218/C - Interactions of novel anticancer drugs with ABC drug efflux transporters and cytochromes P450; their role in multidrug resistance (2018 – 2020)
• 334120/C - The role of pharmacokinetic interactions of new targeted drugs in the modulation of efficacy of cytotoxic drugs in non-small cell lung carcinoma (2020 – 2022)

• 102121/C - Implementation of ex vivo and in vivo lung tumor models for the evaluation of clinical value of dual drug resistance modulators (2021-2023)

Others

• INOMED - Pre-application research into innovative medicines and medical technologies, OP VVV programme, Ministry of Education, Youth and Sport of the Czech republic and EU funds (2019-2022)
• PRIMUS 20/MED/010 - Farmakokinetické mechanizmy lékové rezistence u akutní myeloidní leukémie, jejich ovlivnění a regulace, Charles University (2020-2022)
• START/MED/070 - Unraveling pharmacodynamic principles of acquired resistance to epidermal growth factor receptor inhibitors, Charles University (2021-2023)

• NETPHARM - New Technologies for Translational Research in Pharmaceutical Sciences, OP JAK programme, Ministry of Education, Youth and Sport of the Czech republic and EU funds (2024-2028)

• ONCOPHARM - Pre-application research of drugs for oncological diseases and for the prevention and treatment of serious complications caused by them, OP JAK programme, Ministry of Education, Youth and Sport of the Czech republic and EU funds (2024-2027)